A three-year randomized trial in patients with dysplastic naevi treated with oral beta-carotene.
Ultraviolet irradiation provokes the development of new melanocytic naevi, or changes in existing naevi, leading to repeated surgery of atypical naevi and becoming a continual burden for individuals with many of these lesions. To determine the influence of long-term medication with the radical scavenger beta-carotene on newly developing atypical naevi, a single-centre, randomized, placebo-controlled study, prospective over 3 years, was started double-blind in 62 patients with numerous clinically atypical naevi. Beta-carotene (25 mg) was given twice daily for 36 months in the treatment group (n = 30) and saccharose capsules as placebo in the control group (n = 32). The total number of newly developed naevi in the beta-carotene group (n = 18) was 68 versus 88 in the placebo group (n=21) (not significant). Of 12 different locations on the human body evaluated separately, only in two, the lower arm (p = 0.03) and the feet (p = 0.03), was there a difference for the beta-carotene group in the quantification of naevi. Overall, it is concluded that beta-carotene does not reduce the development of new naevi in patients with numerous atypical naevi.
Bayerl
Christiane
C
Department of Dermatology, Mannheim University Clinic, Germany. christiane.bayerl@haut.ma.uni-heidelberg.de
Schwarz
Beate
B
Jung
Ernst G
EG
D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D004416:Dysplastic Nevus Syndrome / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D019207:beta Carotene / Q000008:administration & dosage / Q000627:therapeutic use*
D019207:beta Carotene